Abstract

PARKINSON’S DISEASE AND ITS MANAGEMENT

Gudivada Himaja Lakshmi*, Musku Srivani, Ishu, Aashutosh Sinwal, Ratana Ram, Vaibhav Sinwal

ABSTRACT

Parkinson's disease is primarily a neurodegenerative disorder characterized by the premature and significant death of dopaminergic neurons in the substantia nigra pars compacta (SNpc). The annual incidence of Parkinson's disease (PD) varies between 5 in 100,000 and over 35 in 100,000 new cases, as estimated through the utilization of healthcare services. Parkinson's disease (PD) is primarily influenced by age, with a median age of onset being 60 years. Parkinson's disease is associated with various clinical manifestations, such as bradykinesia, muscle rigidity, rest tremor, and impairments in postural and ambulatory functions. Levodopa, a potent medication for Parkinson's disease, is frequently administered in conjunction with carbidopa or benserazide. In addition to levodopa, there is a wide range of drug alternatives available for the treatment of motor symptoms associated with Parkinson's disease. The medications encompassed in this
category consist of anticholinergics, amantadine, MAOIs, COMTIs, dopamine agonists, and istradefilline.

Keywords: Parkinson's disease, Substantia nigra pars compacta, Dopamine, Chaperone-mediated autophagy, Catechol-O-methyl transferase inhibitors, Monoamine oxidase inhibitor.